Gadolinium-Based Contrast Agents (GBCAs) Use in Pregnancy

Basic Details
Date Posted
Thursday, April 4, 2019
Status
Complete
Medical Product
gadolinium-based contrast agent (GBCA)
Health Outcome(s)
exposure in pregnancy
Description

Report 1: Gadolinium-Based Contrast Agents (GBCAs) Use in Pregnancy
Request ID: cder_mpl1r_wp051

This report characterizes the use of GBCAs in pregnancy in the Sentinel Distributed Database (SDD). Data from January 1, 2006 to September 30, 2015 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on June 13, 2017.
These results were presented at the Division of Medical Imaging Products (DMIP) Advisory Committee meeting to discuss the risk of brain deposits with repeated use of GBCAs for magnetic resonance imaging (MRI) and to characterize the population using GBCAs. View more information here.

Report 2: Gadolinium-Based Contrast Agents (GBCAs) Use in Pregnancy (an update to cder_mplr_wp051)
Request ID: cder_mpl1p_wp020

This report contains estimates of magnetic resonance imaging (MRI) procedure utilization, with and without GBCAs, before and during pregnancies resulting in a live-born delivery among women of reproductive age in the SDD. Data from January 1, 2006 to January 31, 2018 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on June 28, 2018.